1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Diabetic Retinopathy Market - Global Opportunity Analysis and Industry Forecast, 2014-2022

Diabetic Retinopathy Market - Global Opportunity Analysis and Industry Forecast, 2014-2022

  • April 2017
  • 150 pages
  • ID: 4930975

Summary

Table of Contents

Diabetic Retinopathy Market by Type [Proliferative DR and Non-Proliferative DR), by Management Type (Anti VEGF Drug, Intra-ocular Steroid Injections, Laser Surgeries, and Vitrectomy) - Global Opportunity Analysis and Industry Forecast, 2014-2022

Diabetic retinopathy (DR) is a medical condition of the eye, which is prevalent in a diabetic individual. It is mainly caused due to damage of the blood vessels of the light-sensitive tissue present at the back of the eye. Without timely treatment, the disease may lead to bleeding in the eyes, cloudy vision, and may even destroy the retina. DR is amongst the common cause of loss of vision in the diabetic population. From 1990 to 2010, DR holds the fifth position among the most common causes of preventable blindness and severe visual impairment.

The global diabetic retinopathy market was valued at $966 million in 2015, and is expected to reach $2,490 million by 2022, growing at a CAGR of 14.4% during the forecast period. The market is expected to witness significant growth during the forecast period due to increase in prevalence of diabetes worldwide, rise in geriatric population, growth in incidence of blindness due to diabetes, and augment in focus on awareness which facilitates early diagnosis to control the diseases. Although these factors garner the growth of the market, dearth of skilled ophthalmologists and extended approval time for drugs limit it. On the other hand, emergence of combined therapies for treatment of diabetic macular edema, and the emerging markets of the Asia-Pacific and LAMEA regions are projected to provide several opportunities for the market growth.

The diabetic retinopathy market is segmented on the basis of type, treatment type, and region. Based on type, the market is bifurcated into proliferative DR and diabetic macular edema (DME). On the basis of treatment type, diabetic retinopathy market is segmented into anti VEGF drug, steroid implants, laser surgeries, and vitrectomy. The market is analyzed based on four geographical regions, which include North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
This report provides an extensive analysis of the current and emerging market trends and dynamics in the global diabetic retinopathy market.
Comprehensive analysis of geographical regions is provided to determine the prevailing opportunities in the market.
This study provides the competitive landscape of the market to predict the competitive environment across geographies.
This report entails the detailed quantitative analysis of the current market and estimations from 2014 to 2022 to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
Region- and country-wise diabetic retinopathy market conditions are comprehensively analyzed in the report to understand the regional trends and dynamics.

Diabetic Retinopathy Market Key Segments:

By Type
Proliferative Diabetic Retinopathy
Diabetic Macular Edema (DME)

By Treatment Type
Anti VEGF Drug
Steroid Implants
Laser Surgeries
Vitrectomy

By Region
North America
U.S.
Canada
Mexico
Europe
France
Germany
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
Abbott Laboratories
Alimera Science
Allergan plc
Ampio Pharmaceuticals.
Bayer AG
F. Hoffmann-La Roche
Novartis International AG
Pfizer
Regeneron Pharmaceuticals Inc.
Valeant Pharmaceutical

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Boehringer Ingelheim GmbH
KOWA Company, Ltd.
BCN Peptides S.A.
ThromboGenics NV

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H2 2018

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H2 2018

  • $ 3500
  • October 2018

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Review, H2 2018SummaryType 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes ...

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2018

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2018

  • $ 3500
  • October 2018

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2018SummaryGlucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes ...

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Pipeline Review, H2 2018

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Pipeline Review, H2 2018

  • $ 3500
  • September 2018

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Pipeline Review, H2 2018SummaryTyrosine Protein ...


ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on